Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Welcome, Guest. Please login or register.
February 10, 2016, 02:54:02 AM

Login with username, password and session length

  • Total Posts: 684998
  • Total Topics: 53598
  • Online Today: 210
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 3
Guests: 125
Total: 128


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: NanoViricides Invited to Present at the New York Biotechnology Association 2010  (Read 2566 times)

0 Members and 1 Guest are viewing this topic.

Offline Boze

  • Member
  • Posts: 477

NanoViricides Invited to Present at the New York Biotechnology Association 2010 Annual Meeting

WEST HAVEN, Conn., Apr 19, 2010 (BUSINESS WIRE) -- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that the Company has been invited to present at the New York Biotechnology Association's (NYBA) 2010 Annual Meeting in the "Corporate Showcase" section on April 19, 2010 at 10 am. The Conference is being held at the Marriott Marquis Hotel in Times Square, New York City, from April 19 through April 20.

Dr. Anil Diwan, President of NanoViricides, Inc. will present a review of the Company's technology and its current drug development programs.

The Company is now working towards developing pre-Investigational New Drug ("pre-IND") applications for its drug candidates. A pre-IND is expected to enable the Company to have a meaningful dialog with FDA authorities that should help in the development of data needed for an IND application.

The Company has recently filed a "Universal Form S-3 Shelf Registration" with the Securities and Exchange Commission (SEC) for the sale from time to time of up to $40 million of its securities to raise funding, as needed, for its ongoing drug development programs.

NanoViricides, Inc. is defining a new class of antiviral therapeutics that the Company calls a "nanoviricide(R)". A nanoviricide is designed using information about how a virus interacts with the cell surface to infect the cell. It is well known that these interactions do not change in spite of all the mutations, recombinations, re-assortments, and other genetic changes that the virus undergoes. The Company believes that this fact enables development of nanoviricides that are expected to remain effective in spite of constant mutations and drifts in a given virus. This is extremely important particularly for rapidly changing viruses such as Influenza and HIV, and is also important for other viruses such as Dengue and Ebola.

The Company currently has four commercially important drug candidates in its pipeline. These drug candidates target HIV, all Influenzas, viral diseases of the external Eye, and Herpes Simplex viral infections including cold sores and genital herpes (HSV). In addition, the Company has R&D programs, in collaborations with government and private institutions, evaluating the effectiveness of nanoviricides(R) against several Neglected Tropical Diseases and agents of interest for Biosecurity. These include hemorrhagic fever viruses such as Ebola/Marburg, Dengue, and Rabies, among others.

Our current drug development programs include a pan-influenza drug candidate, "FluCide(TM)". This drug was recently reported to be highly effective against H1N1 influenza in an extremely lethal challenge animal model. All animals treated with FluCide were still surviving when all animals treated with oseltamivir (Tamiflu(R)) were dead within 8 days. FluCide treated animals continued to survive for another whole week beyond those receiving extended oseltamivir treatment. This 14-days-long survival time in our extremely lethal challenge model would suggest indefinite survival in other standardized animal models, according to experts. No other anti-influenza drugs in development have been tested with such severe lethal challenge. FluCide is designed to be effective against all influenza A strains and mutants. We anticipate FluCide to be effective against highly pathogenic avian influenzas such as H7 and H9, the epidemic bird flu virus H5N1 (various clades), the current novel H1N1/2009 virus, seasonal influenza viruses, and their mutations.

The Company has previously reported that its anti-HIV drug candidate was >25X (or >2,500%) more effective than the oral HAART treatment comprising three drugs, on a drug load basis. This study employed a standard SCID-Hu Thy/Liv mouse model. Human lymphocytes are implanted in a surgically modified mouse. The human lymphocytes are thereafter infected with HIV. The mouse is then treated with antiviral drugs in this model. It is very important to note that no adverse events were observed in the nanoviricide treated mice, while the HAART-treated mice exhibited clinical signs of side effects. HAART or "highly active anti-retroviral therapy" is a three-drug combination therapy currently in use in human clinical practice, and is regarded as the most effective therapeutic regimen against HIV. If these preliminary results are confirmed in further animal studies and in human clinical trials, the Company believes that HIVCide(TM) could very well result in a "Functional Cure" for HIV/AIDS.

The Company has reported significant progress in its topical nanoviricide eye drops program. This drug is designed to treat most viral infections of the external eye, including adenoviral epidemic kerato-conjunctivitis (EKC) and herpes keratitis.

The Company also recently reported that it has successfully added a new anti-HSV drug program to its pipeline this year. The Company's topical anti-herpes drug candidate has already demonstrated greater than 10,000-fold (>99.99%, or >4 logs) reduction in virus quantity in cell culture models of HSV-1 infection. Animal model studies of topical and genital herpes are planned.

About New York Biotechnology Association

NYBA is the leading advocate for advancing the success of the biotechnology industry in New York State and is its main representative to state policy makers, the media and communities. NYBA's mission is to support the development and growth of New York's biotechnology industry, and serve our members and the biotechnology community by providing a network for information exchange, shared services and collective action. NYBA's membership comprises bioscience companies, world-class research institutions and related professional services. Under the banner of The Cures Start Here(R), the Association's goal is to amplify the success New York has had and continues to have in discovering major medical advances and growing a vibrant biotech industry.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

SOURCE: NanoViricides, Inc.
Aug08 - Seroconversion
Mar10 - Diagnosis; cd4 690 - VL 19,000
Apr10 - cd4 600
May10 - VL 4,500
Jun10 - started Atripla ; VL 113
Jul 10 - UD vl, CD4 590
Aug 10 - UD, CD4 810, 52%
Nov 10 - UD, CD4 980

Offline Boze

  • Member
  • Posts: 477
One more writeup about the company, more in-depth.


Using Nanotech to Destroy Viruses

By Patrick Cox | December 30, 2009

The company is NanoViricides Inc. (OTCBB: NNVC). NanoViricides works at the interface of several scientific disciplines. It has brought together medicine, biology and chemistry to develop transformational nanotech-enabled anti-viral drugs.

NanoViricides has used new technological tools to custom build a molecular structure that can take out many different kinds of viruses. My colleague Ray Blanco and I were able to interview Dr. Eugene Seymour, NanoViricides’ CEO, at length. He kindly submitted to our extended questioning process so that you could get the inside picture regarding this transformational early-stage company.

NanoViricides’ core TheraCour (therapeutic courier) technology was invented by Dr. Anil R. Diwan. He holds a B.S. in chemical engineering from the Indian Institute of Technology, Bombay, India, and a Ph.D. in biochemical engineering from Rice University. He has 18 years of experience in researching biopharmaceuticals and 12 years of entrepreneurial experience. Dr. Diwan is currently the chairman and president of NanoViricides Inc.

In 2005, Diwan was joined by Dr. Eugene Seymour to found the company. They started the business to market a new class of anti-viral drugs that were based on Diwan’s prior research and intellectual property. Seymour also has a long history in virus research. He was, in fact, a pioneer in the early 1980s, working on the newly appeared disease we now know as HIV.

As an internist practicing immunology when the pandemic began, Seymour treated some of the first patients identified with the virus. He tells us that it was a grueling four-year struggle to figure out what was going on while his patients were dying. In 1989, he founded StatSure, where he led the development of a rapid HIV blood test that gained approval in several countries including Canada, the U.K. and Vietnam. Later, he became a consultant for the U.N. Global Program on AIDS and set up HIV testing programs in several countries.
NanoViricides’ Viral Monkey Wrench

When Diwan and Seymour first founded NanoViricides, they began working on a drug, called HIVCide, that would destroy the HIV virus. Then, the emergence of the widely feared avian flu changed their plans. New drugs were controlling the progression of HIV, while influenza represented a huge untapped market.

Realizing that the flu virus could be attacked with the same basic technology they had developed for HIV, they broadened their focus to other types of viruses. They engineered a variation of their HIV-busting technology called FluCide. This anti-viral drug targets type A influenza, which causes hundreds of thousands of deaths per year.

To understand how their technology works, we need to spend just a little time talking about viruses.

Influenza and other viruses consist of three basic parts. The first is the “payload” at the heart of the virus. In the case of the flu, this payload is RNA. The payload could also be DNA, depending on the type of virus. This genetic material is encased in a protein shell called a capsid. The capsid, in turn, is encased in an envelope, which the virus acquires when it bursts out of an infected cell. This envelope is coated with proteins so that it attaches to a healthy cell, allowing the virus to infect it.

When infected by the flu virus, it normally takes two-three weeks to develop enough immunity to beat back the infection. Since we build up an immune “memory” against particular viral strains, we usually can’t catch one again. However, the flu virus mutates very rapidly. New strains can defeat the immune system.

Before founding NanoViricides, it had occurred to Diwan that there were no truly effective treatments for viral infections. What he created in response is nothing short of a stroke of genius. In applying his knowledge of chemistry and molecular engineering, Diwan treated this problem from a whole new approach and made a great leap forward.
How NanoViricides Kills Viruses

Originally, NanoViricides had intended to carry a drug inside the TheraCour molecule that would attack the virus. Subsequently the company discovered that this was unnecessary. Diwan realized that viruses coat themselves with a membrane that causes them to attach themselves to healthy cells. He also realized that if a structure could be created with characteristics of the virus’s usual target cells, it could fuse to the virus. That process causes the outer membrane of the virus to break down. The capsid streams out, without infecting a cell.

The mere act of attaching to the virus and fusing with its protein coat renders it inert. Since the capsid is unable to infect a cell on its own, the eviscerated virus is then rendered harmless. It can no longer attack any healthy cells.

Dr. Diwan’s revolutionary new drug consists of a base molecule with a number of specialized proteins on its surface. The base molecule, called a nano-micelle, has a spherical shape. Attached to the surface of this “nano-ball” are special proteins designed to specifically neutralize a particular virus. These proteins can be very specialized and targeted, such as for HIV. On the flip side, they can be very broad and generic, such that one can be used as a general-purpose drug that can take out herpes, influenza and other illnesses.

In essence, the nano-micelle developed by NanoViricides mimics the outer surface of the cell. Think of this outer surface as the teeth of a gear. The way a virus attaches to the cell is by having another gear with teeth that perfectly mesh with the cellular gears. When the teeth mesh, it is molecular Velcro. By design, the nano-micelle acts as a perfect decoy for the human cell because the protein profile on its outer surface “fools” the virus into attaching to it instead. The drug throws a molecular “monkey wrench” into the virus’ machinery.

What NanoViricides has done is create a broad-spectrum anti-viral drug that targets all type A influenza, regardless of the strain. Unlike flu vaccines that have to be modified for every new virus strain appearing in the wild, FluCide doesn’t “care.” Since all strains of type A influenza have the same basic properties, it is capable of destroying them all. This not only includes the garden- variety seasonal flu, but also newer variants such as bird and swine flu. It’s the anti-viral equivalent of a nuclear bomb.

Dr. Seymour says a patient treated with FluCide within 24-48 hours of infection simply won’t get sick. If he weren’t getting grants and recognition from other scientists in the field, I might have concluded that he was lying. This is a huge transformational technology.

There are other anti-viral drugs on the market, of course. But NanoViricides’ approach is unique. All the other anti-viral drugs on the market work in different phases of the virus life cycle. For example, one major type actually does remove the viral coating, but only after it enters the cell. Other types act inside the actual cell at the transcription or assembly phase of the virus life cycle. The popular anti-viral drug Tamiflu and swine flu drug Virenza work by preventing the viruses from exiting an infected cell.

Unlike these existing drugs, however, NanoViricides’ technology acts before the virus has had a chance to gain entry into a healthy cell. This is like defeating a besieging enemy army with withering fire before it’s forced the city gates or undermined the defensive walls. The alternative methods used today are the equivalent of a last-ditch house-to-house battle after the defenses have been breached.

These current anti-viral drugs have other drawbacks. They are expensive and resistance develops as the virus mutates. There is also toxicity.

More than 99% of seasonal flu viruses have developed resistance to Tamiflu, according to the CDC. Unlike such drugs, NanoViricides has found no evidence of toxicity or resistance in animal trials. There is no mechanism by which resistance can develop against NanoViricides’ technology. If the surface proteins on the virus mutate away from the ability of the nano-micelle to attach to them, they have also mutated away from the ability to attach to the surface of a human cell. The viruses don’t have a chance.
The Viral Equivalent of Penicillin

Just as penicillin ushered in a new age of antibiotic drugs against bacterial infections, I believe NanoViricides’ revolutionary technology will do the same for virus therapies.

Moreover, NanoViricides has many potential targets for its technology. Currently, it has focused its initial work on herpes, HIV and influenza. The reason for choosing these three is that 95% of all human viruses should be covered by these three versions of NanoViricides’ basic technology. Work is being done with NanoViricides’ drugs at research hospitals, universities and veterinary schools.

For example, the LSU School of Veterinary Medicine has confirmed the effectiveness of its drugs in treating herpes and adenoviruses. This past August, it demonstrated a 99.99% reduction in herpes viral loads in vitro. Southern Research Institute is going to be doing further in vitro research with the NanoViricides drug, and LSU is going to be doing further research in vivo.

Here, NanoViricides sees three major opportunities: eyedrops to eradicate herpes of the eye and topical creams for herpes cold sores and genital herpes. These particular delivery methods don’t destroy the virus in the body, but they do treat flare-ups. It also wants to destroy the herpes virus in its hideout inside the nerve roots and is working on delivery methods.

Next on the list is HIV. In 2008, spectacular results were announced for HIVCide in Israel. Based on the findings there, it was suggested that the company had attained a “functional cure.” This is due to the drug’s ability to decrease the amount of circulating virus and to suppress the virus exiting infected cells in which it was sequestered. HIVCide should allow an affected person to live an essentially normal life, as virus load is so low that the virus cannot be transmitted.

Another possible delivery method for the NanoViricides technology is a skin patch. Since the actual HIV drug is only 20 nanometers across, it should be able to easily pass the transdermal barrier. The goal is to administer an initial loading dose intravenously and then treat the virus over the long term with skin patches. Delivery methods for other viral targets include nasal sprays, bronchial inhalers, intramuscular and — as I mentioned — intravenous injections.

Many government agencies are currently working with NanoViricides in testing the technology. The Walter Reed Army medical research institute is evaluating drugs for the Ebola and Marburg viruses. It is also getting ready to start on dengue. Since it is in the same family of viruses, dengue is a steppingstone to hepatitis C treatment. It also has an HIV program on contract at the Armed Forces Institute of Pathology.

The government of Vietnam has already tested its experimental rabies offering. It was able to salvage 30% of animals that received the treatment. Subsequent trials verified the initial results. The Centers for Disease Control picked up on this and started a large-scale animal study. NanoViricides is also working with the World Wildlife Fund to deliver the Ebola drug to gorillas by blowgun. About 5,000 members of this endangered species died from Ebola in 2002-2003.

The participation of several military medical research institutes underscores the probability that NanoViricides’ approach would be very useful against biological warfare agents. A broad-spectrum anti-viral cocktail could protect against many potential agents in a short time while the bioweapon was analyzed and a more targeted drug could be created. NanoViricides is working with the Department of Defense on this. Upon identifying the exact composition of the biological warfare agent, NanoViricides could then rapidly develop a more targeted drug to neutralize it.

Like a computer operating system, NanoViricides’ modular nano-micelle allows other players to write specific applications for it for less-widespread viruses, simply by designing the right protein connectors to attach to the surface.

The company has demonstrated astonishing early-stage effectiveness for a revolutionary drug with widespread applicability.

Recommendation: buy NanoViricides Inc. (OTCBB:NNVC).

Source: http://breakthroughtechnologyalert.agorafinancial.com/2009/12/30/6-companies-ready-to-change-the-world-and-deliver-your-unending-wealth-in-2010/
Aug08 - Seroconversion
Mar10 - Diagnosis; cd4 690 - VL 19,000
Apr10 - cd4 600
May10 - VL 4,500
Jun10 - started Atripla ; VL 113
Jul 10 - UD vl, CD4 590
Aug 10 - UD, CD4 810, 52%
Nov 10 - UD, CD4 980

Offline Inchlingblue

  • Member
  • Posts: 3,119
  • Chad Ochocinco PETA Ad
I think this technology is very exciting and promising. That's a good in-depth piece from Agora via InvestorsHub.com

I especially love this part:

There is no mechanism by which resistance can develop against NanoViricides’ technology. If the surface proteins on the virus mutate away from the ability of the nano-micelle to attach to them, they have also mutated away from the ability to attach to the surface of a human cell. The viruses don’t have a chance.

Here's another thread about Nanoviricides:

« Last Edit: April 19, 2010, 09:50:44 PM by Inchlingblue »

Offline Boze

  • Member
  • Posts: 477
I read their latest 10-K..the problem is that they need 15mio to run the operation and they have 2. If they don't get it, the business is out. I'm hoping they find the angel investor at this conference they're presenting :)
My only concern is that their technology seems like this panacea for all viruses - flu, hiv, bird-flu - you name it. Souns too good to be true.
Aug08 - Seroconversion
Mar10 - Diagnosis; cd4 690 - VL 19,000
Apr10 - cd4 600
May10 - VL 4,500
Jun10 - started Atripla ; VL 113
Jul 10 - UD vl, CD4 590
Aug 10 - UD, CD4 810, 52%
Nov 10 - UD, CD4 980

Offline Hellraiser

  • Member
  • Posts: 4,153
  • Semi-misanthropic
I read their latest 10-K..the problem is that they need 15mio to run the operation and they have 2. If they don't get it, the business is out. I'm hoping they find the angel investor at this conference they're presenting :)
My only concern is that their technology seems like this panacea for all viruses - flu, hiv, bird-flu - you name it. Souns too good to be true.

Well it would be the viral equivalent of anti-biotics.  As for the money, as soon as they prove they can make money with it by solving problems they won't have a cash problem.  All they need to do is get to that stage AND if you paid attention they're almost to the point where they will start selling shares to fuel their research.  I believe they said that will get them 40million in start up cash.

Offline Inchlingblue

  • Member
  • Posts: 3,119
  • Chad Ochocinco PETA Ad
I read their latest 10-K..the problem is that they need 15mio to run the operation and they have 2. If they don't get it, the business is out. I'm hoping they find the angel investor at this conference they're presenting :)
My only concern is that their technology seems like this panacea for all viruses - flu, hiv, bird-flu - you name it. Souns too good to be true.

Apparently they signed a a Material Transfer Agreement with a major pharmaceutical company for their HSV eye drops.



Offline tommy246

  • Standard
  • Member
  • Posts: 435
This sounds really interesting its only a matter of time i believe and sooner than we all think and hope that we will have alot of better alternatives to haart that will give us a full life span.
jan 06 neg
dec 08 pos cd4 505 ,16%, 1,500vl
april 09 cd4 635 ,16%,60,000
july 09 ,cd4 545,17%,80,000
aug 09,hosptal 18days pneumonia cd190,225,000,15%
1 week later cd4 415 20%
nov 09 cd4 591 ,vl 59,000,14%,started atripla
dec 09  cd4 787, vl 266, 16%
march 2010  cd4 720 vl non detectable -20  20%
june 2010  cd4  680, 21%, ND


Terms of Membership for these forums

© 2016 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.